VAV to support academic research in lipid nanomedicine

VAV Life Sciences has offered to support academic research on advanced lipid-based Novel Drug Delivery Systems (NDDS) used in medical, cosmetics and nutritional therapies. The company has announced a slew of research benefits to universities and academic institutions around the world that take up research in lipids, VAV said in a statement.

To foster academic research in lipids, VAV is offering guidance in analytical techniques, research assistance in characterisation and project guidance. Its subject matter experts will assist university research students in selecting the right grade and writing the project protocol and standard operating procedures. In addition to this, the company will provide complementary lipid samples that are otherwise not easily available and are expensive to procure. Universities and research institutes interested in developing and testing lipids can also avail of VAV’s world-class GMP facilities for research and development, the statement added.

Speaking of the company’s decision, Arun Kedia, Managing Director, VAV Life Sciences said in the statement, “Lipid nanotechnology is a niche science that has a huge potential for treating unresolved diseases in healthcare. Diseases like muscular dystrophy, viral infections, genetic and autoimmune disorders can be treated using lipid-based novel drug delivery systems. However, universities do not take up research due to issues like shortage of highly purified lipid samples, high costs of procurement, and lack of scalability. By supporting research in lipid nanomedicine, we want to encourage more students to take up research and foster wider acceptance for PhD topics from universities.”